MOLM-13 Cells
CAD$690.00*
Products are shipped frozen on dry ice in cryotubes. Each cryotube typically contains 3 × 106 cells for adherent lines or 5 × 106 cells for suspension lines (refer to the batch CoA for details).
General information
| Description | The MOLM-13 cell line is a human acute myeloid leukemia (AML) cell line, originally derived from a patient diagnosed with AML-M5a (acute monocytic leukemia, FAB classification). This line was established at the time of disease relapse, following prior progression from myelodysplastic syndrome (MDS). MOLM-13 cells harbor the MLL-AF9 gene fusion resulting from an insertion, ins(11;9)(q23;p22p23), and exhibit additional chromosomal abnormalities such as trisomy 8, a common feature associated with AML. In terms of phenotypic characteristics, MOLM-13 cells express myeloid and monocyte-associated markers including CD33, CD13, and CD15. However, they lack expression of CD34, a marker of hematopoietic stem and progenitor cells, distinguishing them from other leukemia subtypes. MOLM-13 cells also display monoblastoid morphology with fine chromatin and prominent nucleoli. Functionally, they are capable of differentiation into macrophage-like cells upon exposure to specific cytokines such as interferon-gamma (IFN-γ) and tumor necrosis factor-alpha (TNF-α), which also enhance expression of myelomonocytic markers. MOLM-13 serves as a critical model for studying leukemogenesis, particularly mechanisms underlying MLL-rearranged leukemias. It is also widely used in preclinical research, including the evaluation of novel therapies such as CD70-specific CAR-T cells, which have demonstrated efficacy against MOLM-13 in vitro and in xenograft models. This makes MOLM-13 an invaluable tool for exploring targeted therapeutic approaches for high-risk AML. |
|---|---|
| Organism | Human |
| Tissue | Peripheral blood |
| Disease | Adult acute myeloid leukemia |
| Synonyms | MOLM13, Molm13, Molm 13 |
Characteristics
| Age | 20 years |
|---|---|
| Gender | Male |
| Ethnicity | Japanese |
| Morphology | Lymphoblast-like |
| Growth properties | Suspension |
Regulatory Data
| Citation | MOLM-13 (Cytion catalog number 305393) |
|---|---|
| Biosafety level | 1 |
| NCBI_TaxID | 9606 |
| CellosaurusAccession | CVCL_2119 |
Biomolecular Data
| Antigen expression | CD3 -, CD4 +, CD14 -, CD15 +, CD19 -, CD33 +, CD34 -, cy CD68 +, HLA-DR - |
|---|---|
| Mutational profile | Mutation: FLT3, unexplicit, internal tandem duplication; Gene fusion: KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 |
Handling
| Culture Medium | RPMI 1640, w: 2.0 mM stable Glutamine, w: 2.0 g/L NaHCO3 (Cytion article number 820700a) |
|---|---|
| Supplements | Supplement the medium with 10% FBS |
| Seeding density | Maintain culture between 4 x 105 to 2 x 106 cells/mL |
| Fluid renewal | 2 to 3 times per week |
| Freeze medium | As a cryopreservation medium, we use complete growth medium (including FBS) + 10% DMSO for adequate post-thaw viability, or CM-1 (Cytion catalog number 800100), which includes optimized osmoprotectants and metabolic stabilizers to enhance recovery and reduce cryo-induced stress. |
| Thawing and Culturing Cells |
|
| Incubation Atmosphere | 37°C, 5% CO2, humidified atmosphere. |
| Shipping Conditions | Cryopreserved cell lines are shipped on dry ice in validated, insulated packaging with sufficient refrigerant to maintain approximately −78 °C throughout transit. On receipt, inspect the container immediately and transfer vials without delay to appropriate storage. |
| Storage Conditions | For long-term preservation, place vials in vapor-phase liquid nitrogen at about −150 to −196 °C. Storage at −80 °C is acceptable only as a short interim step before transfer to liquid nitrogen. |
Quality Control & Molecular Analysis
| Sterility | Mycoplasma contamination is excluded using both PCR-based assays and luminescence-based mycoplasma detection methods. To ensure there is no bacterial, fungal, or yeast contamination, cell cultures are subjected to daily visual inspections. |
|---|
Certificate of Analysis (CoA)
| Lot Number | Certificate Type | Date | Catalog Number |
|---|---|---|---|
| 305393-261225 | Certificate of Analysis | 11. Feb. 2026 | 305393 |